Article Details
Retrieved on: 2025-03-16 00:11:50
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Sutro Biopharma (NASDAQ: STRO) presented expanded data from the dose-optimization portion of the REFRαME-O1 trial for luveltamab tazevibulin ...
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here